NCT05874401View on ClinicalTrials.gov

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

PHASE4RecruitingINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
DRUG

Trilaciclib

Participants will receive intravenous trilaciclib infusion

DRUG

Placebo

Participants will receive intravenous placebo infusion

DRUG

Topotecan

Participants will receive intravenous topotecan infusion

Trial Locations (1)

Unknown

RECRUITING

Hospital, Seville

Sponsors

Lead Sponsor

Pharmacosmos A/S
All Listed Sponsors
lead

Pharmacosmos A/S

INDUSTRY